BlossomHill Therapeutics Presented Preclinical KRAS Data

The San Diego-based company shared new trial findings for its experimental pan-KRAS inhibitor, BH-501284.

Updated on Sept. 28, 2026 in Cancer

Isometric editorial illustration of a multi-colored 3D chemical molecule model, representing pharmaceutical research on KRAS inhibitors. — BlossomHill Therapeutics reported positive preclinical results for its new pan-KRAS inhibitor, BH-501284, in treating pancreatic cancer models. AI Illustration. Upload story photo >

Live Poll

Do you believe pharmaceutical companies are making sufficient progress in developing treatments for difficult cancers?

BlossomHill Therapeutics recently presented preclinical data for BH-501284, an oral drug designed to inhibit KRAS mutations, at the AACR Conference on Pancreatic Cancer. The drug showed significant tumor regression in multiple cancer models during early research.

Why it matters

This research aims to overcome limitations found in existing KRAS-targeted therapies by using a novel Switch-II chemical scaffold. The drug is designed to improve both efficacy and patient tolerability while sparing HRAS and NRAS proteins.

In an SPR study utilizing GDP-state KRAS G12D protein, the drug achieved a target residence time exceeding 54 hours. These findings represent preclinical benchmarks for efficacy compared to existing treatment options.

The players

BlossomHill Therapeutics

This San Diego-based biotechnology firm specializes in developing innovative treatments for oncology.

The details

BH-501284 acts as an orally bioavailable, non-covalent, pseudo-irreversible pan-KRAS inhibitor that demonstrated deeper tumor regression than tricomplex inhibitors in pancreatic models. Furthermore, when combined with anti-PD-1 treatment, the drug showed improved survival outcomes in colorectal cancer models.

The AACR Conference on Pancreatic Cancer took place in San Diego from September 25-28, 2026.
BlossomHill Therapeutics intends to file an Investigational New Drug application in Q1 2027.

Health Landscape

This development follows a pattern set by the development of the first FDA-approved KRAS G12C inhibitors by attempting to expand therapeutic options for previously untreatable mutations. It marks a significant milestone in the evolution of targeted molecular oncology treatments.

The potential success of this treatment could eventually provide new options for patients with difficult-to-treat pancreatic, lung, and colorectal cancers. Readers should note that these results are strictly preclinical, and human trial access is not yet available.

The takeaway

Advancements in KRAS inhibition represent a shift toward more durable tumor regression strategies in precision medicine. Patients and caregivers should continue to monitor official clinical trial registries for future human study recruitment updates.